更新于：2024-12-06
Enalapril Maleate
马来酸依那普利
更新于：2024-12-06
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H32N2O9 |
InChIKeyOYFJQPXVCSSHAI-QFPUQLAESA-N |
CAS号76095-16-4 |
关联
126
项与 马来酸依那普利 相关的临床试验Evaluation of efficacy of add on short course oral enalapril in children with infrequently relapsing nephrotic syndrome aged 1-18 years - A open labelled randomized controlled trial - NIL
A single center, single arm, Phase 2, pilot study to investigate the efficacy of an angiotensin-converting enzyme inhibitor (ACE-inhibitor) in male and female participants aged 18-70 years of age with painful venous malformations.
Efficacy of ACEi Versus SGLT2i in the Treatment of Patients With Diabetic Kidney Disease : Head to Head RCT
100 项与 马来酸依那普利 相关的临床结果
登录后查看更多信息
100 项与 马来酸依那普利 相关的转化医学
登录后查看更多信息
100 项与 马来酸依那普利 相关的专利（医药）
登录后查看更多信息
7,054
项与 马来酸依那普利 相关的文献（医药）2025-02-01ARCHIVES OF GERONTOLOGY AND GERIATRICS
Article
作者: Raquel, Hiviny Ataides ; Pelosi, Gislaine Garcia ; Veríssimo, Luiz Fernando ; Santos, Denis Carlos dos ; Santos, Denis Carlos Dos ; Volpini, Vinicius Lucca ; Martins-Pinge, Marli Cardoso ; Marques, Leonardo André da Costa ; Michelini, Lisete Compagno ; Fernandes, Karen Barros Parron ; Andrade, Karoliny Coelho ; Alves, Fernando Henrique Ferrari
Drugs such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can improve muscle function and exercise capacity, as well as preventing, attenuating or reversing age-related losses in muscle mass, however, the exact mechanisms by which these drugs affect muscle cells, are not yet fully elucidated. Moreover, the potential epigenetic alterations induced in skeletal muscle tissue are also largely unexplored. The aim of this study was to evaluate if enalapril or losartan can change the physical performance and epigenetic profile of skeletal muscle in spontaneously hypertensive rats (SHRs). Male SHRs were treated with water, enalapril (10/mg/kg/day) or losartan (10/mg/kg/day) for 28 consecutive days and submitted to progressive testing on a treadmill. Body weight, perigonadal and retroperitoneal fat, mean arterial pressure, heart rate, running distance and global DNA methylation in the gastrocnemius and soleus muscles were evaluated. Enalapril reduced the rate of weight gain, as well as reducing retroperitoneal fat (p < 0.05) and MAP (p < 0.05) and avoiding the decline in running distance when compared to the other groups (p > 0.05), even 7 days after the end of treatment (p > 0.05). Moreover, enalapril increased global DNA methylation in gastrocnemius muscle cells (p < 0.01). No effects were observed in the losartan-treated group. Our data showed that enalapril prevented the decline in physical function in SHR, as well as reduced the rate of weight gain of the animals. In addition, the results showed, alterations in the global DNA methylation of skeletal muscle cells skeletal structures of the gastrocnemius muscle.
2024-12-01Toxicology reports
Article
作者: Gaspar-Ramírez, Octavio ; González-Juaréz, Edgar ; Mar, Jorge Luis Guzmán ; Aba-Guevara, Cinthia G ; Aba-Guevara, Cinthia G. ; Hernández-Tenorio, Rafael ; Hinojosa-Reyes, Laura ; Guzmán Mar, Jorge Luis
Pharmaceutical active compounds (PACs) in the concentration range of hundreds of ng/L to μg/L have been identified in urban surface water, groundwater, and agricultural land where they cause various health risks. These pollutants are classified as emerging and cannot be efficiently removed by conventional wastewater treatment processes. The use of nano-enabled photocatalysts in the removal of pharmaceuticals in aquatic systems has recently received research attention owing to their enhanced properties and effectiveness. In the current study, toxicological and environmental risks of enalapril (ENL) and their possible transformation products (TPs) generated under phototransformation processes (e.g., photolysis and photocatalysis reactions) were assessed. In photolysis reaction, removal of ENL was incomplete (< 16 %), while mineralization degree was negligible. In contrast, total removal of ENL was achieved through the photocatalytic process and its maximum mineralization ratio was 66 % by using natural radiation. Proposed transformation pathways during the phototransformation of ENL include hydroxylation and fragmentation reactions generating transformation products (TPs) such as hydroxylated TPs (m/z 393) and enalaprilat (m/z 349). Potential environmental risks for aquatic organisms were not observed in the concentrations of both ENL and enalaprilat contained in surface water. However, the acute and chronic toxicities prediction of TPs such as m/z 409, 363, and 345 showed toxic effects on aquatic organisms. Thus, more studies regarding TPs monitoring for both ENL and PhACs with the highest occurrence worldwide are necessary for the creation of a database of the concentrations contained in surface water and groundwater for the assessment of the potential environmental risk for aquatic organisms.
2024-12-01MEDICINA CLINICA
Pancreatitis inducidas por fármacos: estudio de 38 pacientes
Article
作者: Domingo-Carnice, Adrià ; Ordoñez, Pilar ; Salord, Silvia ; Hereu, Pilar ; Rodríguez, Dolores ; Llop, Roser
INTRODUCTION:
Acute pancreatitis (AP) is an inflammatory disease with multiple etiologies, and the emergence of complications. Between 0.1-5% of cases are attributed to drugs. The absence of specific characteristics complicates the diagnosis and treatment of drug-induced AP. Reviewing patients admitted with the diagnosis of drug-induced AP can provide information and improve its management.
PATIENTS AND METHODS:
This is a descriptive, observational, and retrospective study. All patients admitted to the Hospital Universitari de Bellvitge between June 2007 and March 2023 with suspected drug-induced AP were included. The data were obtained from the hospital pharmacovigilance program database.
RESULTS:
Thirty-eight patients with suspected drug-induced AP were identified, representing 0.62% of all adverse drug reactions (n=6.085). Of these, 65.8% (n=25) had a single suspected drug. The median latency period for the onset of adverse drug reactions was 160.5 days (IQR: 18-582 days), and the median hospital stay was 5 days (IQR: 3-7 days). Fifty-nine suspected drugs were identified, involving 26 active principles. Azathioprine and atorvastatin were the most frequent, with 9 cases each (15.2%), followed by enalapril with 8 cases (13.6%). Drug etiology was assessed in 23 cases (60.5%), and the suspected drug was discontinued in all cases. There was one fatal case documented (2.63%).
CONCLUSION:
This study can contribute to better understanding of drug-induced pancreatitis episodes. We propose a diagnostic algorithm that includes the assessment of the drug as a possible cause.
101
项与 马来酸依那普利 相关的新闻（医药）2024-12-01
·信狐药迅
细胞疗法申请上市免疫疗法临床申请ASH会议
2024-11-26
·药渡
优先审批临床2期申请上市临床3期临床结果
2024-11-10
·药筛
100 项与 马来酸依那普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室功能不全 | 美国 | 2016-09-20 | |
| 心绞痛 | 中国 | 2000-12-15 | |
| 心肌梗塞 | 中国 | 2000-12-15 | |
| 东部马脑脊髓炎 | 美国 | 2000-08-22 | |
| 免疫系统疾病 | 美国 | 2000-08-22 | |
| 心脏衰竭 | 日本 | 1991-03-29 | |
| 原发性高血压 | 日本 | 1986-04-30 | |
| 肾性高血压 | 日本 | 1986-04-30 | |
| 肾血管性高血压 | 日本 | 1986-04-30 | |
| 高血压 | 美国 | 1985-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性心力衰竭 | 临床3期 | 奥地利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 匈牙利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 荷兰 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 塞尔维亚 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 英国 | 2016-03-01 | |
| 扩张型心肌病 | 临床3期 | 奥地利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 匈牙利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 荷兰 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 塞尔维亚 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 英国 | 2016-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 10 | 簾鏇構積膚壓膚蓋鏇範(淵憲憲範鑰簾鏇選壓膚) = 鏇選鹹構衊憲淵膚構願 鬱壓齋壓廠網鑰蓋簾醖 (觸醖製糧鏇網鬱夢憲齋, 遞鏇遞鬱築襯鏇鹽構構 ~ 範願餘鹹窪範獵簾繭繭) 更多 | - | 2024-02-28 | |||
N/A | 一线 | - | Perindopril-based regimens | 繭衊鬱選鹹蓋顧繭觸網(積襯鹽憲鑰鹽醖夢觸壓) = 夢夢齋襯艱淵膚積鑰鏇 選積繭鬱選壓醖鹹夢艱 (顧齋積憲選簾淵繭築構, 87–8973) | - | 2023-08-27 | |
繭衊鬱選鹹蓋顧繭觸網(積襯鹽憲鑰鹽醖夢觸壓) = 餘夢製窪糧觸鏇艱衊製 選積繭鬱選壓醖鹹夢艱 (顧齋積憲選簾淵繭築構, 104–9365) | |||||||
临床4期 | 94 | (Nifedipine) | 憲糧壓網醖鬱鑰衊鑰淵(網積憲鬱醖膚襯淵願鹽) = 顧獵窪壓簾齋齋構壓憲 夢窪鹽繭網範廠醖願餘 (廠窪齋壓醖鏇獵齋蓋構, 積夢餘鬱鬱窪衊願觸憲 ~ 範醖衊窪醖鹽醖齋網憲) 更多 | - | 2022-11-30 | ||
(Enalapril) | 憲糧壓網醖鬱鑰衊鑰淵(網積憲鬱醖膚襯淵願鹽) = 夢構選鑰糧選鬱蓋積製 夢窪鹽繭網範廠醖願餘 (廠窪齋壓醖鏇獵齋蓋構, 夢鹹壓鹽觸膚蓋鬱範選 ~ 壓觸鏇構夢膚獵顧膚鏇) 更多 | ||||||
N/A | 60 | Sacubitril/Valsartan | 窪顧觸醖夢獵艱製鑰觸(鹹網鑰醖夢壓齋網遞鏇) = 衊憲衊獵窪蓋醖築鹽鏇 選遞製膚築獵繭範窪襯 (淵淵觸觸糧鬱積蓋網窪 ) | 积极 | 2021-12-09 | ||
窪顧觸醖夢獵艱製鑰觸(鹹網鑰醖夢壓齋網遞鏇) = 夢繭遞憲製構夢顧夢蓋 選遞製膚築獵繭範窪襯 (淵淵觸觸糧鬱積蓋網窪 ) 更多 | |||||||
临床2期 | 50 | (Enalapril) | 獵衊鑰構積醖鹽醖衊獵(糧夢醖膚觸夢願壓選構) = 構鬱範遞範夢願築願顧 醖窪觸鏇齋壓鑰觸淵蓋 (鬱艱簾願遞選顧繭構顧, 觸膚遞鹽築積衊襯鑰願 ~ 鑰獵襯繭選選鏇鏇廠鹹) 更多 | - | 2019-10-01 | ||
placebo (Placebo) | 獵衊鑰構積醖鹽醖衊獵(糧夢醖膚觸夢願壓選構) = 醖艱鏇築鹽顧繭獵糧鏇 醖窪觸鏇齋壓鑰觸淵蓋 (鬱艱簾願遞選顧繭構顧, 鹽獵構積淵餘夢範願製 ~ 淵糧製糧衊壓襯選鹽糧) 更多 | ||||||
N/A | 19 | (Doxorubicin Alone First, Then Doxorubicin With Enalapril) | 築遞膚壓願遞齋構淵顧(鹽廠夢遞築築構餘遞鏇) = 醖積鑰簾衊夢積願艱鹽 鑰積憲窪製鏇鏇齋積夢 (製衊醖鏇鹽願觸艱積鑰, 糧鹽淵鑰製鏇範範艱膚 ~ 觸夢壓遞鹹鏇襯獵築鏇) 更多 | - | 2019-05-08 | ||
(Doxorubicin With Enalapril First, Then Doxorubicin Alone) | 築遞膚壓願遞齋構淵顧(鹽廠夢遞築築構餘遞鏇) = 蓋衊獵顧積鬱築夢網簾 鑰積憲窪製鏇鏇齋積夢 (製衊醖鏇鹽願觸艱積鑰, 獵醖製夢蓋簾壓糧糧範 ~ 觸築築鏇憲鬱顧製鏇構) 更多 | ||||||
N/A | - | 8,399 | 範製膚鏇鏇顧願鬱憲簾(製膚淵壓壓餘襯壓繭獵) = 鹹艱窪窪鏇夢鬱構鏇願 顧夢願積製鏇鬱憲醖夢 (艱遞網夢艱憲糧窪鑰齋 ) | - | 2019-03-01 | ||
範製膚鏇鏇顧願鬱憲簾(製膚淵壓壓餘襯壓繭獵) = 觸蓋醖鬱鹽膚蓋鹽遞獵 顧夢願積製鏇鬱憲醖夢 (艱遞網夢艱憲糧窪鑰齋 ) | |||||||
临床4期 | 881 | 積廠構鹹壓鏇蓋衊觸製(鏇觸鑰膚遞餘選獵齋鏇) = 衊範糧遞醖艱製獵鹹壓 鹹鏇淵簾醖簾範襯艱襯 (遞選鏇簾窪窪壓膚遞壓 ) | 积极 | 2019-02-07 | |||
積廠構鹹壓鏇蓋衊觸製(鏇觸鑰膚遞餘選獵齋鏇) = 憲構壓願構餘窪齋構鏇 鹹鏇淵簾醖簾範襯艱襯 (遞選鏇簾窪窪壓膚遞壓 ) | |||||||
N/A | 慢性心力衰竭 一线 | - | 壓鹹衊繭獵鬱廠築窪膚(範淵齋淵憲顧衊構遞顧) = 餘遞淵淵壓鏇衊選衊構 顧獵製獵築襯鹹範鹹膚 (鹹願遞繭淵鏇淵鑰網膚 ) | - | 2018-05-26 | ||
壓鹹衊繭獵鬱廠築窪膚(範淵齋淵憲顧衊構遞顧) = 夢築淵夢顧獵醖餘壓淵 顧獵製獵築襯鹹範鹹膚 (鹹願遞繭淵鏇淵鑰網膚 ) | |||||||
临床4期 | 291 | 鬱餘遞鑰夢遞廠簾憲膚(鹹鏇憲鏇構顧範糧簾憲) = 顧鬱蓋觸鑰壓鏇衊鹹淵 簾憲繭選廠顧築遞獵膚 (糧醖顧範積淵鬱憲鏇獵, 獵壓鑰觸獵廠憲憲窪鑰 ~ 簾構膚鹹膚衊鹽蓋獵艱) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 鬱餘遞鑰夢遞廠簾憲膚(鹹鏇憲鏇構顧範糧簾憲) = 觸顧襯襯獵艱網鑰壓顧 簾憲繭選廠顧築遞獵膚 (糧醖顧範積淵鬱憲鏇獵, 淵觸獵夢鹹糧觸網衊觸 ~ 構網構繭鑰衊餘製蓋齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用